Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review

References

• Seborrheic keratosis. Mayo Clinic. 2022. https://www.mayoclinic.org/diseases-conditions/seborrheic-keratosis/symptoms-causes/syc-20353878
   Google Scholar
• Jackson JM, Alexis A, Berman B, et al. Current understanding of seborrheic keratosis: prevalence, etiology, clinical presentation, diagnosis, and management. J Drugs Dermatol. 2015;14(10):1119–1125.
   PubMed Web of Science ®Google Scholar
• Baumann LS, Blauvelt A, Draelos ZD, et al. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). J Am Acad Dermatol. 2018;79(5):869–877. Article
   PubMed Web of Science ®Google Scholar
• Greco MJ, Bhutta BS. Seborrheic Keratosis. StatPearls. StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
   Google Scholar
• Aclaris Therapeutics, Inc. Aclaris Therapeutics reports second quarter 2019 financial results, provides business strategy update and provides update on clinical and commercial developments. GlobeNewswire News Room. 2019. https://www.globenewswire.com/news-release/2019/08/08/1899526/0/en/Aclaris-Therapeutics-Reports-Second-Quarter-2019-Financial-Results-Provides-Business-Strategy-Update-and-Provides-Update-on-Clinical-and-Commercial-Developments.html
   Google Scholar
• Gonzalez M, Ramos V, Tan C. Topical treatments for seborrheic keratosis: a systematic review. J Dermatol Nurses’ Assoc. 2020;12(2):305–312.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam D, Burkhart CG. Hydrogen peroxide use for chemical destruction in seborrheic keratosis: a review. TODJ. 2019;13(1):68–70.
   Google Scholar
• Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209305s000lbl.pdf
   Google Scholar
• Smith SR, Xu S, Estes E, et al. Anatomic site–specific treatment response with 40% hydrogen peroxide (W/W) topical formulation for raised seborrheic keratoses: Pooled analysis of data from two phase 3 studies. J Drugs Dermatol. 2018;17(10):1092–1098.
   PubMed Web of Science ®Google Scholar
• DuBois J, Grande K, Bradshaw M, et al. Effectiveness of hydrogen peroxide topical solution 40% and 45% (w/w) in patients with seborrheic keratoses on the trunk, extremities, and face: Results of a phase 2, randomized, double-blind, vehicle-controlled, parallel group study. J Am Acad Dermatol. 2019;81(4):AB197.
   Web of Science ®Google Scholar
• DuBois JC, Jarratt M, Beger BB, et al. A-101, a proprietary topical formulation of High-Concentration hydrogen peroxide solution: a randomized, Double-Blind, Vehicle-Controlled, parallel group study of the Dose-Response profile in subjects with seborrheic keratosis of the face. Dermatol Surg. 2018;44(3):330–340.
   PubMed Web of Science ®Google Scholar
• DuBois J, Grande K, Rhodes T, et al. Assessing patients’ satisfaction with hydrogen peroxide topical solution, 40% for treatment of raised seborrheic keratoses. J Drugs Dermatol. 2020;19(12):1184–1191.
   PubMed Web of Science ®Google Scholar
• DuBois J, Grande K, Bradshaw M, et al. Safety of hydrogen peroxide topical solution 40% and 45% (w/w) in patients with seborrheic keratoses on the trunk, extremities, and face: Results of a phase 2, randomized, double-blind, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2019;81(4):AB271.
   Web of Science ®Google Scholar
• Mitsuhashi Y, Kawaguchi M, Hozumi Y, et al. Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol. 2005;32(6):420–423.
   PubMed Web of Science ®Google Scholar
• Yousefi M, Nabaei L, Ghasemnia H, et al. Eficacy of calcipotriol in the treatment of seborrheic keratosis: a pilot study. Iran J Dermatol. 2013;16(66):132–136.
   Google Scholar
• Herron MD, Bowen AR, Krueger GG. Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol. 2004;43(4):300–302.
   PubMed Web of Science ®Google Scholar
• Sutedja EVA, Suwarsa OKI, Febrina DIA. Comparison of the effectiveness of topical 5-fluorouracil, topical calcipotriol, and cryosurgery in seborrheic keratosis. J Dermatol Nurses’ Assoc. 2020;12(2):85–88.
   Google Scholar
• Wijayanti W, Nurdin AR, Widita W, et al. A case of atypical seborrheic keratoses mimicking porokeratosis. Forum Nordic Dermato Venerol. 2020;25(3):1–3.
   Google Scholar
• Fluorouracil. Uses, Interactions, Mechanism of Action | DrugBank Online. Updated October 17, 2022. https://go.drugbank.com/drugs/DB00544%C2%A0
   Google Scholar
• Tsuji T, Morita A. Giant seborrheic keratosis on the frontal scalp treated with topical fluorouracil. J Dermatol. 1995;22(1):74–75.
   PubMedGoogle Scholar
• Burkhart CG, Burkhart CN. Use of a keratolytic agent with occlusion for topical treatment of hyperkeratotic seborrheic keratoses. Skinmed. 2008;7(1):15–18.
   PubMedGoogle Scholar
• Campione E, Cosio T, Di Prete M, et al. Effectiveness of a cosmetic device containing a combination of alpha- and beta-hydroxy acids, urea, and thuja for the treatment of seborrheic keratoses. J Cosmetic Dermatol. 2022;21(5):2113–2119.
   PubMed Web of Science ®Google Scholar
• Chun EY, Lee JB, Lee KH, et al. Focal trichloroacetic acid peel method for benign pigmented lesions in Dark-Skinned patients. Dermatol Surg. 2004;30(4 Pt 1):512–516; discussion 516.
   PubMed Web of Science ®Google Scholar
• Komalasari DN, Djawad K, Nurdin AR, et al. Unusual clinical manifestation of seborrheic keratosis on the scalp successfully treated with topical trichloroacetic acid: an atypical case report. Pan Afr Med J. 2020;37:1–6.
   Web of Science ®Google Scholar
• Lacarrubba F, Rita Nasca M, Elisa Verzì A, et al. A novel topical agent in the treatment of seborrheic keratoses: an open-label pilot study with clinical and dermoscopic evaluation. J Am Acad Dermatol. 2017;76(6):AB19.
   Web of Science ®Google Scholar
• Tribó MJ, Aladren S, Garre A, et al. A novel nitrizinc complex® solution for topical treatment of seborrhoeic keratosis: an interventional clinical study. Eur J Dermatol. 2019;29(2):203–208.
   PubMed Web of Science ®Google Scholar
• Feuerman EJ, Katzenelson V, Halevy S. Solcoderm in the treatment of solar and seborrheic keratoses. Dermatologica. 1984;168(SUPPL. 1):33–35.
   PubMedGoogle Scholar
• Klaus MV, Wehr RF, Rogers Iii RS, et al. Evaluation of ammonium lactate in the treatment of seborrheic keratoses. J Am Acad Dermatol. 1990;22(2 Pt 1):199–203.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. February 25, 2010. https://www.accessdata.fda.gov/drugsatfda_docs/anda/2010/078548Orig1s000.pdf
   Google Scholar
• Imiquimod. Uses, Interactions, Mechanism of Action | DrugBank Online. Updated October 17, 2022. https://go.drugbank.com/drugs/DB00724
   Google Scholar
• Cuevas P, Angulo J, Salgüero I, et al. Clearance of seborrhoeic keratoses with topical dobesilate. BMJ Case Reports. 2012;2012(jun21 1):bcr0120125628.
   PubMedGoogle Scholar
• Rosen R, Freeman M, Zibert JR, et al. Ingenol mebutate 0 05% gel reduces cancer cells in squamous cell carcinoma in situ and shows marginal effect in seborrhoeic keratosis. Br J Dermatol. 2014;171:50.
   Google Scholar
• Afify AA, Hana MR. Comparative evaluation of topical diclofenac sodium versus topical ibuprofen in the treatment of seborrheic keratosis. Dermatol Ther. 2020;33(6):e14370.
   PubMed Web of Science ®Google Scholar
• Callender VD, Frankel EH, Weiss JS, et al. An open-label study of the safety of A-101, a 40% hydrogen peroxide topical solution, in patients with seborrheic keratoses. J Am Acad Dermatol. 2018;79(3):AB39.
   Web of Science ®Google Scholar
• DuBois J, Grande K, Schnyder J, et al. Assessing patient satisfaction with hydrogen peroxide topical solution, 40% (w/w) treatment of seborrheic keratoses on the face, neck, and décolletage: Objectives and design of the phase IV, openlabel SK-FAN study. J Clin Aesthetic Dermatol. 2019;12(5):S32.
   Google Scholar
• Peredo M, Murphy E, Karibayeva D. Clinical experience with 40% hydrogen peroxide topical solution for the treatment of seborrheic keratosis. J Drugs Dermatol. 2019;18(7):s173–s177.
   PubMed Web of Science ®Google Scholar
• Schlesinger TE, Favre C. Enhancing outcomes in seborrheic keratosis: using a novel treatment solution. J Drugs Dermatol. 2019;18(7):s178–s182.
   PubMed Web of Science ®Google Scholar